SSE1806, a podophyllotoxin derivative (a natural antimitotic agent), functions as a microtubule/tubulin inhibitor, exhibiting potent anticancer and antiproliferative properties. It demonstrates a GI50 for inhibiting cancer cell growth between 1.29-21.15 μM. This compound induces mitotic disruption and G2/M phase arrest, upregulates p53 expression, and suppresses the growth of colon cancer organoids. Notably, SSE1806 can counteract multidrug resistance in cell lines that overexpress MDR-1 [1].